Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Hosp Pediatr ; 12(10): 866-877, 2022 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-36102129

RESUMO

OBJECTIVE: The Nephrotoxic Injury Negated by Just-in-Time Action (NINJA) program is a multicenter, quality improvement initiative that identifies patients at risk for nephrotoxic medication-associated acute kidney injury (NTMx-AKI). The purpose of this study was to (1) evaluate the prevalence and types of NTMx exposures and (2) determine the prevalence of NTMx-AKI categorized by service. Exploratory analysis evaluated potential associations between hospital measures and NTMx-AKI. METHODS: This is a single-center, retrospective chart review of NTMx exposures from January 2019 to June 2020 in noncritically ill children. High NTMx exposures were defined as ≥3 simultaneous nephrotoxins or ≥3 days of either intravenous vancomycin or aminoglycoside. Prevalence of high NTMx and NTMx-AKI rate were normalized to 1000 patient days. A retrospective case-control analysis assessed for potential associations with development of NTMx-AKI. RESULTS: There were 609 NTMx exposures in 565 patients and 44 (7.2%) episodes of NTMx-AKI. The NTMx prevalence rate per 1000 patient days was highest among liver, neurosurgery, and gastroenterology services. The most commonly used NTMx were vancomycin, intravenous contrast, and nonsteroidal antiinflammatory drugs. The NTMx-AKI rate in exposed patients ranged from 0% to 14% across service lines. AKI was most often attributable to vancomycin. Univariable analyses suggest type and duration of NTMx exposure are associated with development of NTMx-AKI but not with severity. CONCLUSIONS: NTMx exposures and NTMx-AKI are variable across services. Partnerships with antimicrobial stewardship and multicenter studies are needed to modify NTMx-AKI risk. Ongoing surveillance is needed in patients who do not have normalization of creatinine before discharge.


Assuntos
Injúria Renal Aguda , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Injúria Renal Aguda/induzido quimicamente , Injúria Renal Aguda/epidemiologia , Aminoglicosídeos , Criança , Creatinina , Humanos , Estudos Retrospectivos , Fatores de Risco , Vancomicina/efeitos adversos
2.
J Pediatr Hematol Oncol ; 41(5): 371-375, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-30475303

RESUMO

A nationwide shortage of intravenous (IV) sodium bicarbonate required institutions to explore alternative options for urinary alkalinization for high-dose methotrexate (HDMTX). Children's Hospital Colorado implemented a protocol utilizing oral alkalinizing agents as alternatives to intravenous sodium bicarbonate during the shortage. The purpose of this study was to determine the safety and efficacy of oral alkalinization strategies for HDMTX administration. This retrospective study was conducted at a pediatric institution and evaluated cycles of HDMTX administered with at least one dose of oral sodium bicarbonate tablets or sodium citrate-citric acid oral solution. The time to achieve urine pH of ≥7 was 3.48 hours from the start of alkalinization. A median dose of 66.4 mEq/m/day of oral sodium bicarbonate was administered to maintain a urine pH of ≥7 until methotrexate was cleared. Gastrointestinal side effects occurred with 43% of HDMTX cycles and patients switched to IV sodium acetate in 25.5% of HDMTX cycles, primarily due to inadequate alkalinization or intolerance. During a shortage of IV sodium bicarbonate, oral alkalinization is an effective strategy for most patients to allow for administration of HDMTX.


Assuntos
Antiácidos/uso terapêutico , Concentração de Íons de Hidrogênio , Metotrexato/administração & dosagem , Bicarbonato de Sódio/provisão & distribuição , Urina/química , Administração Intravenosa , Antiácidos/administração & dosagem , Antiácidos/efeitos adversos , Criança , Feminino , Gastroenteropatias/induzido quimicamente , Humanos , Masculino , Metotrexato/efeitos adversos , Estudos Retrospectivos , Acetato de Sódio/administração & dosagem , Bicarbonato de Sódio/administração & dosagem
3.
J Pediatr Pharmacol Ther ; 22(5): 332-337, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-29042833

RESUMO

OBJECTIVES: Medication errors involving chemotherapy are a serious source of avoidable medical harm that can result in chemotherapy-related adverse drug events. Efforts to reduce errors in the past decade have largely focused on chemotherapy errors at the prescriber level, using computerized or automated technology, but little has been done to ensure chemotherapy is administered accurately at the nursing level. The current study implemented a pharmacist-led, supplemental, institution-specific training program to nursing staff regarding the use of chemotherapy and to address knowledge deficits in newly hired nursing personnel. METHODS: Inpatient pediatric oncology nurses were eligible to participate in a 3-session educational program regarding chemotherapy principles, adverse event management, and supportive care. Pre- and posttests were administered during the sessions to assess baseline and acquired knowledge. An attitudes survey was given to nurses prior to their first session and after the last session to assess the nurse's comfort with administration and management of chemotherapy. RESULTS: Posttest scores following program implementation show a significant increase in baseline knowledge. Scores increased by 14.1% (p < 0.001) overall; they increased 6% (p = 0.266), 22% (p = <0.001), and 16.5% (p = <0.001) after sessions 1, 2, and 3, respectively. All respondents requested additional classes for orientation or continuing education. CONCLUSIONS: A pharmacist-led, educational program significantly improves knowledge of chemotherapy administration and monitoring in pediatric oncology nurses and was well received by participants as an additional training opportunity.

4.
J Pediatr Pharmacol Ther ; 22(3): 203-206, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28638302

RESUMO

OBJECTIVES: Antihemophilic factor human is a factor VIII product used to supplement those with hemophilia. Recent data show treatment benefit and cost saving opportunities if factor products are administered as a continuous infusion rather than conventional bolus dose. This method has not been widely used given the lack of evidence for safe and effective use beyond 3 hours from preparation. The objectives of this study were to determine the physical and chemical stability and sterility of antihemophilic factor human over a 7-day period. METHODS: Antihemophilic factor human was obtained from the manufacturer. Baseline stability and sterility were determined by factor activity levels along with bacterial and fungal cultures. These tests were also evaluated over a span of 7 days at room temperature and under refrigeration. RESULTS: Each sample was inspected at the time of delivery and showed no visible signs of physical changes. Factor activity levels were maintained between 88% and 102% of baseline measurements. No growth was observed for bacterial or fungal cultures in any sample after 4 weeks of incubation. CONCLUSIONS: Antihemophilic factor human maintained physical stability and chemical stability and remained sterile for the 7-day period, allowing extended stability and continuous infusions to be considered.

5.
J Pediatr Hematol Oncol ; 39(4): 241-248, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28060118

RESUMO

Cytomegalovirus (CMV) is a frequent complication of hematopoietic stem cell transplant in pediatric patients, with significant morbidity and mortality. Antiviral drugs are used as prophylactic, preemptive or therapeutic medicines; however, no uniform guidelines exist for the best strategy to prevent CMV disease. Resistance to standard antiviral therapies can lead to further difficulty in managing CMV disease. Studies for investigational therapies are underway and could provide options for treatment of resistant CMV, while limiting toxicities associated with currently used antiviral therapies.


Assuntos
Infecções por Citomegalovirus/tratamento farmacológico , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Adolescente , Antivirais/uso terapêutico , Criança , Pré-Escolar , Infecções por Citomegalovirus/etiologia , Infecções por Citomegalovirus/prevenção & controle , Feminino , Humanos , Masculino , Neoplasias/complicações , Neoplasias/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...